Improving CAR‑NK cell therapy for BCMA‑positive B‑cell cancers
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
['FUNDING_U01'] · UNIVERSITY OF SOUTHERN CALIFORNIA · NIH-11179272
Researchers are designing and refining engineered receptors so off-the-shelf natural killer (NK) cells can better find and kill BCMA-positive B‑cell cancers.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTHERN CALIFORNIA (nih funded) |
| Locations | 1 site (Los Angeles, UNITED STATES) |
| Trial ID | NIH-11179272 on ClinicalTrials.gov |
What this research studies
From my perspective as a patient, the team is using computer models and lab experiments to redesign the parts of CARs that tell NK cells when and how to attack cancer. They pair computational modeling with detailed measurements of signaling proteins (phospho-proteomics) to see how different CAR designs change NK cell activation and killing. The researchers will make several NK-optimized CAR constructs that target BCMA, which is commonly found on certain B‑cell cancers, and test which designs trigger the strongest, safest responses. The goal is validated CAR designs that could guide new off-the-shelf NK cell therapies for BCMA-positive cancers.
Who could benefit from this research
Good fit: Ideal candidates for eventual therapies based on this work would be people with BCMA-positive B‑cell cancers, such as many cases of relapsed or refractory multiple myeloma.
Not a fit: Patients whose tumors do not express BCMA or who have non‑B‑cell solid tumors are unlikely to benefit from BCMA-targeted CAR‑NK approaches.
Why it matters
Potential benefit: If successful, this work could lead to safer and more effective off-the-shelf NK cell therapies that better target BCMA-positive B‑cell cancers like multiple myeloma.
How similar studies have performed: BCMA-targeted CAR‑T therapies have shown strong clinical activity in multiple myeloma and early CAR‑NK studies show safety and promise, but NK‑optimized CAR designs remain a newer and less-tested approach.
Where this research is happening
Los Angeles, UNITED STATES
- UNIVERSITY OF SOUTHERN CALIFORNIA — Los Angeles, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FINLEY, STACEY DELERIA — UNIVERSITY OF SOUTHERN CALIFORNIA
- Study coordinator: FINLEY, STACEY DELERIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.